http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MA-42207-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b44a39d61c7b866d3939aa0feca0bcb2 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate | 2016-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d29efc7f934e0876f936e22a609b836 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea18571c1e4ab795333e9865926a985a |
| publicationDate | 2018-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MA-42207-A1 |
| titleOfInvention | Methods and compositions for the treatment of pathological conditions associated with abnormal inflammatory responses |
| abstract | The present invention relates to chemical entities (eg, a compound exhibiting an activity as a mitochondrial decoupling agent or a pharmaceutically acceptable salt and / or hydrate and / or co-crystal thereof, for example, a compound, such as a niclosamide or a pharmaceutically acceptable salt and / or hydrate and / or co-crystal thereof, for example, a compound, such as a niclosamide analogue, or a salt and / or a hydrate and / or a pharmaceutically acceptable co-crystal |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11564896-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11744812-B2 |
| priorityDate | 2015-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4477 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419479559 |
Total number of triples: 17.